INTERIM REPORT
1 JANUARY – 31 MARCH 2022

We strive to improve people's lives

SEK
2579
m

NET SALES

SEK
435
m

EBITA

35
%

EARNINGS GROWTH
R12 MONTHS

86
%

P/WC

Kristina Willgard Q12022

A successful quarter!

We start 2022 with a strong first quarter, where sales increased by 49 percent to SEK 2,579 million and EBITA increased by 34 percent to SEK 435 million, resulting in an EBITA margin of 16.9 percent. This growth comes mainly from our acquisitions and the strong expansion in Europe in recent years.

A leading player in Life Science

AddLife is a listed Swedish Medtech company active on the European market. AddLife owns and acquires companies in niche segments with offerings aimed primarily at the healthcare sector, from research to medical care. The subsidiaries are divided into two business areas. Labtech offers products, solutions and a wide range of diagnostic services, biomedical research and laboratory analysis. Medtech offers products, solutions and services in medical technology and home care.

Acquisitions during the quarter

During the quarter, the previously announced acquisitions of MBA Incorporado S.L and Telia Health Monitoring were completed and after the end of the quarter, two more acquisitions, BioCat GmBh and O'Flynn Medical Ltd, were completed. In total, these acquisitions are estimated to contribute with annual net sales of approximately SEK 830m and approximately 350 employees.

Forvarv Q1 2022